CA - NervGen Pharma awarded up to $1.5M US Department of Defense funding
- NervGen Pharma ( OTCQX:NGENF ) has been awarded up to $1.5M in US Department of Defense funding from the Military Operational Medicine Research Program to evaluate NervGen's NVG-291-R as a therapeutic to enable accelerated and enhanced restoration of function following peripheral nerve injury.
- The work described in the project would establish preclinical proof-of-concept for the use of NVG-291-R to improve the rate and extent of nerve regeneration following peripheral nerve crush injury or transection followed by repair.
- The funding was made through the US Army Medical Research and Development Command's other transaction agreement with the Medical Technology Enterprise Consortium (or MTEC).
For further details see:
NervGen Pharma awarded up to $1.5M US Department of Defense funding